Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/9/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Tom Geimer?

Tom Geimer

Managing Director

Madeleine Pharmaceuticals Inc

HQ Phone:  (608) 960-3864

Direct Phone: +61 *** *** ***direct phone

Email: t***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Madeleine Pharmaceuticals Inc

9630 Foxford Road

Chanhassen, Minnesota,55317

United States

Company Description

Madeleine is developing Vastiras® and two further natural protein replacement therapies that not only can provide additional care in the hospital but at home and during the development of acute exasperations of congestion. Madeleine is pioneering patient centr... more

Find other employees at this company (9)

Web References(22 Total References)


Our Team | Madeleine Pharmaceuticals

madeleine-pharma.com [cached]

Tom Geimer
Tom Geimer


Madeleine Pharmaceuticals | Cettera

cettera.com [cached]

Madeleine Pharmaceuticals Pty Ltd (Madeleine) was founded in June 2009 by the Entrepreneur in Residence (EIR) for BioInnovation SA (BioSA), namely: Dr. Tom Geimer (Founder).
More on Madeleine by contacting Tom Geimer tom.geimer@madeleine-pharma.com


Tom Geimer | Madeleine Pharmaceuticals

madeleine-pharma.com [cached]

Tom Geimer
Dr. Geimer co-founded Madeleine and Madeleine Pty. He moved to South Australia in 2008; co-founded Terra Rossa Capital and progressed selected opportunities to companies including Madeleine Pty. With partners at Sage, and co-founders Leigh Berryman and Larry Mahan, Tom assembled the present team. Tom has held positions in various start-ups, corporate management, and on the London stock exchange. Tom contributed to the establishment of venture capital in Europe focused on biotechnology. As a Partner at Apax, he led the successful Genmab investment, a record breaking deal and the spinout Zymogenetics from Novo Nordisk. Tom was a founder of U3 Pharma that sold to Daiichi Sankyo in another record breaking transaction. His expertise in spinouts led to the formation of Madeleine Pty as a spin-out of Hospira (now Pfizer). Tom has a molecular biology (Honors) degree from the University of Wisconsin at Madison and a PhD in veterinary science from Hannover, Germany. He holds a certification in veterinary anesthesiology from Cornell and an MBA from London Business School (Rotary Scholar).


Team | Madeleine Pharmaceuticals

madeleine-pharma.com [cached]

Tom Geimer
Chief Executive Officer Tom Geimer Chief Executive Officer


Team | Madeleine Pharmaceuticals

madeleine-pharma.com [cached]

Tom Geimer -Managing Director
Tom is Managing Director of Madeleine. He has held positions in various start-ups, corporate management in Germany and on the stock market in the city of London. Tom was previously a Venture Partner with Heidelberg Innovation following five years as a Senior Partner with Apax. Tom was involved with several of the larger transactions at Apax including three corporate spin-outs. In addition, his extensive network resulted in his securing several proprietary deals including Wilex, Zymogenitics, Metagen, BioImage and Atugen. Tom acted as the primary team member on Genmab which returned over 500% IRR and is one of, if not, the top ranking healthcare transaction in the 25 year history of Apax. He was also founder of U3 Pharma which was subsequently sold to Daiichi Sankyo. In 2008, Tom moved at the invitation of the government to Australia as the Entrepreneur in Residence for Biotechnology in South Australia, co-founded Terra Rossa Capital and subsequently progressed selected opportunities to companies, for example, Madeleine. Tom has a degree in molecular biology (Honors) from University of Wisconsin at Madison and a PhD in veterinary science from Hannover, Germany. He also holds a certification in veterinary anesthesiology from the Cornell University and an MBA from London Business School, where he was an international Rotary Scholar.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory